Cargando…
Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy
A double-blinded parallel randomized controlled clinical trial was conducted on two groups of colorectal cancer patients to study the therapeutic benefit of orally administered bovine lactoferrin (bLF) on colorectal cancer patients having age ranges from 20 to 71 years and who received 5-fluorouraci...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897438/ https://www.ncbi.nlm.nih.gov/pubmed/27350986 http://dx.doi.org/10.1155/2014/184278 |
_version_ | 1782436159586041856 |
---|---|
author | Moastafa, Tarek M. El-Sissy, Alaa El-Din Elsayed El-Saeed, Gehan K. Koura, Mai Salah El-Din |
author_facet | Moastafa, Tarek M. El-Sissy, Alaa El-Din Elsayed El-Saeed, Gehan K. Koura, Mai Salah El-Din |
author_sort | Moastafa, Tarek M. |
collection | PubMed |
description | A double-blinded parallel randomized controlled clinical trial was conducted on two groups of colorectal cancer patients to study the therapeutic benefit of orally administered bovine lactoferrin (bLF) on colorectal cancer patients having age ranges from 20 to 71 years and who received 5-fluorouracil and leucovorin calcium. Test group (15 patients) received oral bLF 250 mg/day beside chemotherapy for three months. Control group (15 patients) received chemotherapy only. Serum lactoferrin (LF), serum glutathione-s-transferase enzyme (GST), interferon gamma (INF-γ), tumor marker carcinoembryonic antigen (CEA), renal function tests, hepatic function tests, and complete blood count were measured for both groups before and at the end of the trial. Although, there was a significant effect of oral bLF (250 mg/day) that indicated a significant improvement in mean percent of change of all parameters 3 months after treatment, there was no significant difference between results of patients in the test group and patients in the control group after treatment. This result suggests that oral bLF has significant therapeutic effect on colorectal cancer patients. Our study suggests that daily administration of bLF showed a clinically beneficial effect to colorectal cancer patients with better disease prognosis but that needs further looking into. |
format | Online Article Text |
id | pubmed-4897438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48974382016-06-27 Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy Moastafa, Tarek M. El-Sissy, Alaa El-Din Elsayed El-Saeed, Gehan K. Koura, Mai Salah El-Din Int Sch Res Notices Clinical Study A double-blinded parallel randomized controlled clinical trial was conducted on two groups of colorectal cancer patients to study the therapeutic benefit of orally administered bovine lactoferrin (bLF) on colorectal cancer patients having age ranges from 20 to 71 years and who received 5-fluorouracil and leucovorin calcium. Test group (15 patients) received oral bLF 250 mg/day beside chemotherapy for three months. Control group (15 patients) received chemotherapy only. Serum lactoferrin (LF), serum glutathione-s-transferase enzyme (GST), interferon gamma (INF-γ), tumor marker carcinoembryonic antigen (CEA), renal function tests, hepatic function tests, and complete blood count were measured for both groups before and at the end of the trial. Although, there was a significant effect of oral bLF (250 mg/day) that indicated a significant improvement in mean percent of change of all parameters 3 months after treatment, there was no significant difference between results of patients in the test group and patients in the control group after treatment. This result suggests that oral bLF has significant therapeutic effect on colorectal cancer patients. Our study suggests that daily administration of bLF showed a clinically beneficial effect to colorectal cancer patients with better disease prognosis but that needs further looking into. Hindawi Publishing Corporation 2014-10-28 /pmc/articles/PMC4897438/ /pubmed/27350986 http://dx.doi.org/10.1155/2014/184278 Text en Copyright © 2014 Tarek M. Moastafa et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Moastafa, Tarek M. El-Sissy, Alaa El-Din Elsayed El-Saeed, Gehan K. Koura, Mai Salah El-Din Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy |
title | Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy |
title_full | Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy |
title_fullStr | Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy |
title_full_unstemmed | Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy |
title_short | Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy |
title_sort | study on the therapeutic benefit on lactoferrin in patients with colorectal cancer receiving chemotherapy |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897438/ https://www.ncbi.nlm.nih.gov/pubmed/27350986 http://dx.doi.org/10.1155/2014/184278 |
work_keys_str_mv | AT moastafatarekm studyonthetherapeuticbenefitonlactoferrininpatientswithcolorectalcancerreceivingchemotherapy AT elsissyalaaeldinelsayed studyonthetherapeuticbenefitonlactoferrininpatientswithcolorectalcancerreceivingchemotherapy AT elsaeedgehank studyonthetherapeuticbenefitonlactoferrininpatientswithcolorectalcancerreceivingchemotherapy AT kouramaisalaheldin studyonthetherapeuticbenefitonlactoferrininpatientswithcolorectalcancerreceivingchemotherapy |